Published in Mov Disord on March 01, 1994
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna) (2005) 1.97
Clinical relevance of botulinum toxin immunogenicity. BioDrugs (2012) 1.64
Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry (1998) 1.52
Position paper on the use of botulinum toxin in cerebral palsy. UK Botulinum Toxin and Cerebral Palsy Working Party. Arch Dis Child (1998) 1.51
A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut (2000) 1.48
A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry (1996) 1.12
Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol (2010) 0.99
Immunogenicity of botulinum toxins. J Neural Transm (Vienna) (2012) 0.99
Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics (2009) 0.98
Use of botulinum toxin in the neurology clinic. Nat Rev Neurol (2010) 0.95
Deep brain stimulation for torsion dystonia in children. Childs Nerv Syst (2007) 0.94
Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. J Neurol (2011) 0.89
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. J Neural Transm (Vienna) (2013) 0.88
Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor Other Hyperkinet Mov (N Y) (2014) 0.86
Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A. J Neurol Neurosurg Psychiatry (1995) 0.86
Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines. Clin Interv Aging (2011) 0.85
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D (2015) 0.84
Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol (2009) 0.83
Treatment strategies for dystonia. Expert Opin Pharmacother (2010) 0.83
Noncosmetic periocular therapeutic applications of botulinum toxin. Middle East Afr J Ophthalmol (2010) 0.82
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophthalmol (2011) 0.82
Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review. Aesthet Surg J (2017) 0.81
Percutaneous chemical nerve block with ultrasound-guided intraneural injection. Eur Radiol (2008) 0.79
Obturator nerve block with botulinum toxin type B for patient with adductor thigh muscle spasm -a case report-. Korean J Pain (2011) 0.79
Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. J Neural Transm (Vienna) (2013) 0.79
Emerging opportunities for serotypes of botulinum neurotoxins. Toxins (Basel) (2012) 0.77
Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol (2013) 0.77
Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J Neural Transm (Vienna) (2009) 0.76
Future aspects of botulinum neurotoxins. J Neural Transm (Vienna) (2007) 0.76
Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data. Clin Ophthalmol (2011) 0.75
Effects of intraplantar botulinum toxin-B on carrageenan-induced changes in nociception and spinal phosphorylation of GluA1 and Akt. Eur J Neurosci (2016) 0.75
Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord (2015) 0.75
Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia. Patient Prefer Adherence (2016) 0.75
Development of botulinum toxin therapy. West J Med (1995) 0.75
Unmet Needs in the Management of Cervical Dystonia. Front Neurol (2016) 0.75
Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study. Head Face Med (2009) 0.75
Botulinum Toxin in Migraine Treatment. Noro Psikiyatr Ars (2013) 0.75
Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. Front Neurol (2017) 0.75
The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol (2013) 0.75
Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins (Basel) (2017) 0.75
[Essential blepharospasm : Practice-oriented therapy with botulinum toxin employing reduced treatment intervals]. Ophthalmologe (2012) 0.75
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 6.03
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet (1997) 5.39
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet (1995) 5.11
A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med (2001) 4.35
Autoimmune diseases. N Engl J Med (2001) 3.60
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc Natl Acad Sci U S A (1984) 3.35
Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry (1980) 3.19
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. Neuroepidemiology (1997) 2.96
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol (1996) 2.86
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
The DYT1 phenotype and guidelines for diagnostic testing. Neurology (2000) 2.39
The Fc receptors of primary and cultured phagocytic cells studied with homogeneous antibodies. J Immunol (1978) 2.38
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25
Idiopathic cervical dystonia: clinical characteristics. Mov Disord (1991) 2.21
Accuracy of family history data on Parkinson's disease. Neurology (2003) 2.15
Functional brain networks in DYT1 dystonia. Ann Neurol (1998) 2.14
Oral and genital tardive pain syndromes. Neurology (1994) 2.07
What is it? Case 3, 1991: moaning in a man with parkinsonian signs. Mov Disord (1991) 2.05
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Distant effects of local injection of botulinum toxin. Muscle Nerve (1987) 2.02
Use of monoclonal antibodies to identify shared idiotypes on human antibodies to native DNA from patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1983) 2.02
Motor blocks in Parkinson's disease. Neurology (1992) 2.01
Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol (1989) 2.00
Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology (1994) 1.97
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Revisiting and revising suppressor T cells. Immunol Today (1992) 1.92
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord (1987) 1.92
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
A new Fc receptor on mouse macrophages binding IgG3. J Exp Med (1981) 1.87
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. I. An associated sodium-activated transphosphorylation. J Biol Chem (1966) 1.86
Immunization with a peptide surrogate for double-stranded DNA (dsDNA) induces autoantibody production and renal immunoglobulin deposition. J Exp Med (1998) 1.84
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci (1992) 1.79
Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet (1993) 1.78
Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve (1991) 1.77
Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology (1990) 1.77
Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol (2001) 1.75
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol (1988) 1.72
Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci U S A (1996) 1.71
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Selegiline and mortality in Parkinson's disease. Ann Neurol (1996) 1.67
Delayed-onset cerebellar syndrome. Arch Neurol (1996) 1.65
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. II. Effects of N-ethylmaleimide and other sulfhydryl reagents. J Biol Chem (1966) 1.62
Chronic manganese intoxication. Arch Neurol (1974) 1.61
Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A (1997) 1.61
TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. J Leukoc Biol (1992) 1.60
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology (1998) 1.60
The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody. J Immunol (1987) 1.58
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Mutational analysis of an autoantibody: differential binding and pathogenicity. J Exp Med (1994) 1.53
Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab (1993) 1.52
High dosage anticholinergic therapy in dystonia. Neurology (1983) 1.52
Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry (1998) 1.52
Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol (1995) 1.51
Laserlight cues for gait freezing in Parkinson's disease: an open-label study. Parkinsonism Relat Disord (2010) 1.51
Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain (1998) 1.50
Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology (1991) 1.46
Identification of a new V kappa gene family that is highly expressed in hybridomas from an autoimmune mouse strain. J Immunol (1990) 1.46
Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology (1981) 1.46
The clinical spectrum of posthypoxic myoclonus. Mov Disord (2000) 1.46
Movement disorder in reflex sympathetic dystrophy: a case proven to be psychogenic by surveillance video monitoring. Mov Disord (1997) 1.45
Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord (1989) 1.44
"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology (1974) 1.44
Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology (1979) 1.43
Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci U S A (2000) 1.43
The relationship between parafunctional masticatory activity and arthroscopically diagnosed temporomandibular joint pathology. J Oral Maxillofac Surg (1999) 1.43
Supraglottic and pharyngeal sensory abnormalities in stroke patients with dysphagia. Ann Otol Rhinol Laryngol (1996) 1.42
Welcome news about levodopa, but uncertainty remains. Ann Neurol (1998) 1.42
Regional distribution of gamma-aminobutyric acid (GABA) in brain of the rhesus monkey. J Neurochem (1968) 1.41
Tourette syndrome. Arch Neurol (1996) 1.39
Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology (1991) 1.39
Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology (1986) 1.38
Definition of dystonia and classification of the dystonic states. Adv Neurol (1976) 1.36
A novel class of anti-DNA antibodies identified in BALB/c mice. J Exp Med (1991) 1.35
Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol (1997) 1.34
Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope (1986) 1.33
An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol (1988) 1.33
Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B. Infect Immun (1999) 1.32
Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology (2002) 1.32
Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. Am J Hum Genet (1990) 1.31
IgG1 and IgG2b share the Fc receptor on mouse macrophages. J Immunol (1980) 1.31
All classes of murine IgG antibody mediate macrophage phagocytosis and lysis of erythrocytes. J Immunol (1980) 1.29
Physiologic and pathologic tremors. Diagnosis, mechanism, and management. Ann Intern Med (1980) 1.28
Primary sensory symptoms in parkinsonism. Neurology (1976) 1.26
Predictors of reported condom use in central Harlem youth as conceptualized by the health belief model. J Adolesc Health (1997) 1.25
Osteoporosis in a north american adult population with celiac disease. Am J Gastroenterol (2001) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol (2000) 1.22
Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol (2006) 1.22
Familial systemic lupus erythematosus. Presence of a cross-reactive idiotype in healthy family members. J Clin Invest (1985) 1.21
Age-related changes in pharyngeal and supraglottic sensation. Ann Otol Rhinol Laryngol (1994) 1.21